AstraZeneca-Daiichi Sankyo Datopotamab deruxtecan gets USFDA priority review in pretreated EGFR-mutated non-small cell lung cancer Ruchika Sharma14 Jan 2025 2:30 PM ISTDatopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo.
Daiichi Sankyo Datroway approved in Japan for breast cancer Ruchika Sharma29 Dec 2024 12:00 PM ISTTokyo: Daiichi Sankyo's DATROWAY (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor...
AstraZeneca, Daiichi Sankyo voluntarily withdraws datopotamab deruxtecan application in EU for lung cancer Ruchika Sharma25 Dec 2024 11:30 AM ISTCambridge: AstraZeneca and Daiichi Sankyo have voluntarily withdrawn the marketing authorisation application (MAA) in the EU for datopotamab...
AstraZeneca-Daiichi Sankyo Datopotamab deruxtecan gets USFDA Breakthrough Therapy Designation for previously treated advanced EGFR-mutated non-small cell lung cancer Ruchika Sharma10 Dec 2024 12:30 PM ISTCambridge: AstraZeneca has announced that Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the...
AstraZeneca, Daiichi Sankyo submits Datopotamab deruxtecan new BLA for accelerated approval in US for lung cancer Ruchika Sharma14 Nov 2024 3:15 PM ISTAstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan...
CDSCO panel Approves AstraZeneca's Protocol Amendment proposal for Datopotamab Deruxtecan study Dr. Divya Colin7 Nov 2024 6:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca's...
AstraZeneca Pharma India gets CDSCO Panel Nod to study anti-cancer drug Datopotamab deruxtecan/Rilvegostomig Dr. Divya Colin6 July 2024 6:00 PM ISTNew Delhi: The drug major AstraZeneca Pharma India has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
AstraZeneca, Daiichi Sankyo Datopotamab deruxtecan application accepted in US for pretreated metastatic HR-positive, HER2-negative breast cancer Ruchika Sharma3 April 2024 12:30 PM ISTAstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the...
EMA validates marketing authorisation applications for AstraZeneca, Daiichi Sankyo datopotamab deruxtecan in lung, breast cancer Ruchika Sharma6 March 2024 3:25 PM ISTCambridge: The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s...
AstraZeneca Gets CDSCO Panel nod to study Anti-cancer Drug Datopotamab Deruxtecan and Durvalumab Dr. Divya Colin23 Feb 2024 6:00 PM ISTNew Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee SEC functional under the Central Drug Standard Control...
AstraZeneca-Daiichi Sankyo application for Datopotamab deruxtecan accepted in US for patients with previously treated advanced nonsquamous non-small cell lung cancer Ruchika Sharma19 Feb 2024 4:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US...
Justify Durvalumab dose: CDSCO Panel Tells AstraZeneca on Study of Dato-DXd and Durvalumab Dr. Divya Colin8 Jan 2024 6:00 PM ISTNew Delhi: Reviewing the drug major AstraZeneca's Phase III clinical trial protocol of the anti-cancer drug of Dato-DXd and Durvualumab, the Subject...
